Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.9B
90M shares
52-week range
$21.15 – $93.61
63% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
15.1
EV / FCF (TTM)
110
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
www.liquidia.comNo one on the platform currently holds LQDA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 8,100 | $305.7K |
No one on the platform has traded LQDA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 1031.2% | 192.5% | ||||
| Profit Margin % | -43.5% | -390.1% | -1310.5% | |||
| Free Cash Flow Margin % | -25.3% | -284.4% | -1117.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +10.1% on the P/E track.
At today's price, your expected annual return is +22.7% on the P/E track.
At today's price, your expected annual return is +31.5% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $739M | +380.3% | $3.07 | $2.28–$4.11 | 21.8× | 5 |
| 2027 | $1.2B | +65.9% | $5.57 | $4.08–$8.15 | 12.0× | 5 |
| 2028 | $1.4B | +16.3% | $6.56 | $4.71–$7.39 | 10.2× | 5 |
| 2029 | $1.6B | +12.4% | $7.72 | $5.61–$9.06 | 8.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.76 | $0.74 | -2.4% |
| 2026-05-11 | $0.34 | $0.52 | +52.9% |
| 2026-03-05 | $0.08 | $0.15 | +87.5% |
| 2025-11-03 | $-0.45 | $-0.04 | +91.1% |
| 2025-08-12 | $-0.43 | $-0.49 | -14.0% |
| 2025-05-08 | $-0.42 | $-0.45 | -7.1% |
| 2025-03-19 | $-0.38 | $-0.46 | -21.1% |
| 2024-11-13 | $-0.37 |
| $-0.37 |
| +0.0% |
| $2.2B |
| — |
| GLPGGalapagos N.V. | $27.98 | +1.71% | $1.8B | — |
| GPCRStructure Therapeutics Inc. | $38.12 | -2.13% | $2.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MNKD To equate $LQDA market cap rise (which led to incredible share price rise) to MNKD market cap rise (which led to essentially flat share price over the last 10 years or just about any period of time) is so stupid that only @NatesNotes can be that stupid to convince suckers to subscribe to his newsletter. Thank you for your attention to this matter. #nateisanidiot #factsmatter #numbersdon'tLie I attack Nate because he is a freaking moron for various reasons. One of which is how he brags how smart he is and how dumb others are. My god, a normal person who is not pumping his newsletter would shut up, after saying super buy under $5 and buy under $10 for so many years.
View on StockTwits ↗@NatesNotes is spewing BS again. He must assumes his subscribers are suckers. Nate said earlier today that "my experiences with the stock suggest anyone who is a “long-term short” is almost certainly underwater at this point…". This comment is just as stupid as the one he made equating MNKD mkt cap to $LQDA mkt cap to suggest MNKD ceo is just as good as LQDA ceo. LOL. That's how stupid he assumes his subscribers are. MNKD is at $3.58 right now. On Aug 4, MNKD closed at $3.95. Today MNKD closed at $3.93. As of Aug 4, 2026: 1 D > +4.21% 5 D > +1.28% 1 M > -12.39% 6 M > -31.49% YTD > -30.16% 1 Y > 1.02% 5 Y > -1.74% All (since Aug 2004) > -94.89% ca.finance.yahoo.com/quote/... #factsmatter #nateisstupid #nate'sOwnWords
View on StockTwits ↗
$LQDA And just like that.. Another 2% shaved off the share price.. Anyone with hopes and dreams that this stock will trade anywhere near $90 again is just delusional unfortunately.. Just buy puts and recuperate your missed gains on the inevitable drop under $50 soon.
View on StockTwits ↗
$LQDA Patients continually added, best in class drug, and projected 1 billion run rate. There was a larger drawdown than this earlier THIS YEAR. This dip will pay me just as the priors one have. See you over 100.
View on StockTwits ↗$LQDA 2% down just as I said.. We’re definitely on track to trade below $50 by end of October. Looking forward to seeing it down 2% again tomorrow.
View on StockTwits ↗$LQDA Can’t wait to see it down another 2% today. My puts will and won’t stop generating free money 🤑
View on StockTwits ↗$LQDA Such an easy stock to hold puts and sell calls on. Looking forward to seeing my puts 10x when it trades under $30 soon
View on StockTwits ↗
$MNKD guys - $LQDA is $67.85!!! If price action doesn’t tell you who is right and who is wrong I can’t help you. Keep following the resident loser Nate who has been recommending this as a buy since $50+
View on StockTwits ↗
@Shaybe16569 all out with the exception of a few shares from $6.15 and some November and January calls. Totally fucking agree. I sold $LQDA , $TVTX , &$SLS for way more of this. I’ve been fucked by euro trash management before who are too cocky and don’t play well with wall street. There are always exceptions to the rule, but that’s where I’m at. I’m in reset mode now. Trying to find my footing. Doing DD for another banger not in in the EU. I might buy a few more if it drops to $7-$8
View on StockTwits ↗
$LQDA United Therapeutics, Inc. (UTHR) — Chairman and CEO Martine A. Rothblatt reported today that he sold 9,500 shares at $489.20 per share (totaling $4.65 million).
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.